<DOC>
	<DOCNO>NCT00836056</DOCNO>
	<brief_summary>The objective study compare rate extent absorption clindamycin 300 mg capsule ( test ) versus Cleocin HCl ( reference ) , administer 1 x 300 mg capsule fast condition .</brief_summary>
	<brief_title>Clindamycin 300 mg Capsules Healthy Subjects Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<criteria>Childbearing potential nonchildbearing potential female male , nonsmoker , ≥ 18 ≤65 year age . Nonchildbearing potential female subject define follow : 1 . Postmenopausal state : absence menses 12 month prior drug administration hysterectomy bilateral oophorectomy least 6 month prior drug administration . 2 . Surgically sterile : hysterectomy , bilateral oophorectomy , tubal ligation least 6 month prior drug administration . Capable consent . Clinically significant illness within 4 week prior administration study medication . Clinically significant surgery within 4 week prior ot administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion Medical SubInvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive test hepatitis B , hepatitis C , HIV screen . EGC abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . BMI≥ 30.0kg/m2 . History significant alcohol abuse within six month prior screen visit indication regular use fourteen unit alcohol per week ( 1 Unit= 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ) positive alcohol breath test screening . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen visit positive urine drug screen screen . History allergic reaction clindamycin relate drug ( e.g . lienomycin ) . History allergic reaction heparin . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , haematologic , immunologic , psychiatric , metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Difficulty swallow study medication . Use tobacco product 90 day precede drug administration . Any food allergy , intolerance , restriction special diet could , opinion Medical Subinvestigator , contraindicate subject 's participation study . A depot injection implant drug within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood prior administration study medication follow : 1. less 300 mL whole blood within 30 day , 2 . 300 mL 500 mL whole blood within 45 day , 3. 500 mL whole blood within 56 day prior drug administration . Intolerance venipuncture . Subjects clinically significant history tuberculosis , epilepsy , asthma , diabetes , psychosis , glaucoma eligible study . Subjects unable understand unwilling sign Informed Consent Form . Clinically significant history diarrhea subsequent administration antibacterial agent antibiotic . Additional exclusion criterion female : 1 . Breastfeeding subject . 2 . Positive urine pregnancy test screen 3 . Female subject childbearing potential unprotected sexual intercourse nonsterile male partner ( i.e . male sterilized vasectomy least 6 month ) within 14 say prior study drug administration . Acceptable method contraception : 1. condom + spermicide , 2. diaphragm + spermicide , 3. intrauterine contraceptive devise ( place least 4 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>